OTCM
SMHGF
Market cap3.56bUSD
, Last price
USD
Name
Simcere Pharmaceutical Group Ltd
Chart & performance
P/E
—
P/S
—
EPS
0.52
Vol. 1Y
—
Shs. 5Y
-0.94%
Rev. 5Y
11.39%
Div Yld LY
—
Div Yld TTM
—
Revenues
7.73b
+16.52%
Net income
1.34b
+83.32%
CFO
2.01b
+44.74%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing pharmaceutical products. These medicines are distributed to various clients, including distributors, pharmacy chains, and fellow drug manufacturers within China. The company strategically focuses on a diverse range of therapeutic areas, notably oncology, central nervous system conditions, autoimmune diseases, anti-infective treatments, and cardiovascular health, among others. Its extensive product portfolio features key medications such as Sanbexin (an edaravone and dexborneol concentrated solution for injection), Endostar (a recombinant human endostatin injection), ENWEIDA (an envafolimab injection), Softan (rosuvastatin calcium tablets), ZAILIN (amoxicillin in granules, dispersible tablets, or capsules), Iremod (iguratimod tablets), Antine (diclofenac sodium sustained-release capsules or gel), and Orencia (an abatacept injection). Additionally, Simcere offers specialized promotional services for pharmaceutical goods. Demonstrating its commitment to innovation, the group has established a strategic regional licensing collaboration with Vivoryon Therapeutics N.V. This partnership aims to develop and commercialize novel therapies for Alzheimer's disease by targeting the neurotoxic amyloid protein N3pE (pGlu-Aß). Established in 1995, Simcere Pharmaceutical Group Limited is headquartered in Nanjing, China.
Key people
Danny Chen
Senior Vice President · since 2022
Senior Vice President · since 2021
Tong Zhu
Senior Vice President · since 2022
Gaobo Zhou
Chief Investment Officer · since 2022
Xianghua Cheng
Vice President
Ruiwen Shi
Vice President · since 2021
Feng Wang
Vice President · since 2021
Jinsheng Ren
Executive Chairman of the Board, Chief Executive Officer, Founder
Renhong Tang
Executive Director · since 2022
Xi Wang
Executive Director · since 2023
Mookerjee Bijoyesh
Chief Medical Officer · since 2022
Yushan Wan
Chief Financial Officer, Executive Director, Joint Company Secretary · since 2022
Wai Ling Wong
Joint Company Secretary · since 2024
Non-Executive Independent Director · since 2019
Non-Executive Independent Director · since 2023
Non-Executive Independent Director · since 2019
Non-Executive Independent Director · since 2019
Legal address
43/F
AIA Tower
183 Electric Road
North Point 999077
HK
AIA Tower
183 Electric Road
North Point 999077
HK
Headquarters
699 - 18 Xuanwu Avenue
Xuanwu Distric
Nanjing, JS 210000
CN
Xuanwu Distric
Nanjing, JS 210000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||